CHOP Plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term benefits: A Case Report and Literature Review
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype of Non-Hodgkin’s lymphoma characterized by an aggressive phenotype and poor outcome in the vast majority of cases. Substantial portions of patients either have no prior diagnosis of celiac disease or have a subacute course of celiac disease followed by EATL diagnosis.
We report a case of a 72-year-old African American male without history of gastrointestinal intolerance who presented with acute abdominal pain and weight loss leading to the eventual diagnosis of gastric EATL. Despite an initial promising clinical and radiographic response to CHOP plus alemtuzumab, the disease rapidly progressed with a fatal outcome.
Discussion and Conclusion
This case and review of the literature highlights the features of this uncommon disease and addresses both the diagnostic and therapeutic challenges of this aggressive malignancy. We also discuss our experience with the use of FDG-PET in monitoring treatment response.
- Al-Toma A, Verbeek WH, Hadithi M, et al. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007;56:1373–8. CrossRef
- Alaedini A, Green PH. Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med 2005;142:289–98.
- Anderson RP, Degano P, Godkin AJ, et al. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000;6:337–42. CrossRef
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86. CrossRef
- Daum S, Weiss D, Hummel M, et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut 2001;49:804–12. CrossRef
- Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920–4. CrossRef
- Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001;120:636–51. CrossRef
- Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000;18:795–803.
- Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian–Danish study. J Clin Oncol 2007;25:3746–52. CrossRef
- Green PH, Cellier C. Celiac disease. N Engl J Med 2007;357:1731–43. CrossRef
- Honemann D, Prince HM, Hicks RJ, et al. Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Ann Hematol 2005;84:118–21. CrossRef
- Obermann EC, Diss TC, Hamoudi RA, et al. Loss of heterozygosity at chromosome 9p21 is a frequent finding in enteropathy-type T-cell lymphoma. J Pathol 2004;202:252–62. CrossRef
- Verbeek WH, Mulder CJ, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med 2006;355:1396–7. author reply 1397. CrossRef
- Vivas S, Ruiz de Morales JM, Ramos F, et al. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med 2006;354:2514–5. CrossRef
- Wohrer S, Chott A, Drach J, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol 2004;15:1680–3. CrossRef
- CHOP Plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term benefits: A Case Report and Literature Review
Journal of Gastrointestinal Cancer
Volume 38, Issue 1 , pp 59-62
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- enteropathy-associated T-cell lymphoma (EATL)
- celiac disease
- Author Affiliations
- 1. Department of Internal Medicine, University of Chicago Hospitals, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, 60637, USA
- 2. Section of Hematopathology, Department of Pathology, University of Chicago Hospitals, Chicago, IL, USA
- 3. Section of Hematology/Oncology, Department of Medicine, University of Chicago Hospitals, Chicago, IL, USA